CN108778423A - 阿片类新生儿脱瘾综合征的治疗和预防 - Google Patents

阿片类新生儿脱瘾综合征的治疗和预防 Download PDF

Info

Publication number
CN108778423A
CN108778423A CN201780015234.5A CN201780015234A CN108778423A CN 108778423 A CN108778423 A CN 108778423A CN 201780015234 A CN201780015234 A CN 201780015234A CN 108778423 A CN108778423 A CN 108778423A
Authority
CN
China
Prior art keywords
opioid
opioid antagonist
brain
naltrexol
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780015234.5A
Other languages
English (en)
Chinese (zh)
Inventor
沃尔夫冈·萨迪
约翰·奥伯迪克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State Innovation Foundation
Original Assignee
Ohio State Innovation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State Innovation Foundation filed Critical Ohio State Innovation Foundation
Publication of CN108778423A publication Critical patent/CN108778423A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
CN201780015234.5A 2016-01-08 2017-01-06 阿片类新生儿脱瘾综合征的治疗和预防 Pending CN108778423A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662276691P 2016-01-08 2016-01-08
US62/276,691 2016-01-08
PCT/US2017/012452 WO2017120417A1 (en) 2016-01-08 2017-01-06 Treatments and prevention of opioid neonatal abstinence syndrome

Publications (1)

Publication Number Publication Date
CN108778423A true CN108778423A (zh) 2018-11-09

Family

ID=59274434

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780015234.5A Pending CN108778423A (zh) 2016-01-08 2017-01-06 阿片类新生儿脱瘾综合征的治疗和预防

Country Status (7)

Country Link
US (3) US10925870B2 (cg-RX-API-DMAC7.html)
EP (1) EP3400066B1 (cg-RX-API-DMAC7.html)
JP (1) JP7061568B2 (cg-RX-API-DMAC7.html)
CN (1) CN108778423A (cg-RX-API-DMAC7.html)
AU (1) AU2017206041B2 (cg-RX-API-DMAC7.html)
DK (1) DK3400066T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017120417A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113573711A (zh) * 2019-01-04 2021-10-29 伊瑟治疗公司 治疗药物或酒精依赖性的方法
CN114096249A (zh) * 2019-07-09 2022-02-25 奥瑞克索股份公司 用于鼻腔递送的药物组合物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3066284A1 (en) * 2018-04-09 2019-10-17 Katana Pharmaceuticals, Inc. Oxytocin compositions and methods of use
US20240325379A1 (en) * 2021-07-06 2024-10-03 Aether Therapeutics Inc. Low-dose naltrexol and uses thereof
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4743601A (en) * 2000-03-15 2001-09-24 Wolfgang Sadee Neutral antagonists and use thereof in treating drug abuse
DE602004009449T2 (de) * 2003-07-25 2008-07-24 Euro-Celtique S.A. Behandlung von entzug
EP1817023A4 (en) * 2004-11-16 2010-08-18 Limerick Biopharma Inc METHODS AND COMPOSITIONS FOR TREATING PAIN
CA2702680A1 (en) 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
WO2009079489A1 (en) * 2007-12-17 2009-06-25 The Ohio State University Research Foundation Methods for screening of opioid receptor neutral antagonists and inverse agonists and uses thereof
WO2010065930A1 (en) * 2008-12-04 2010-06-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DEBELAK ET AL: "Buprenorphine+naloxone", 《THE AMERICAN JOURNAL ON ADDICTIONS》 *
S.L. WIEGAND, ET AL.: "Buprenorphine and Naloxone Compared With Methadone Treatment in Pregnancy", 《OBSTET GYNECOL.》 *
国家食品药品监督管理总局执业药师资格认证中心: "《药学专业知识(1)第七版2015》", 28 February 2015 *
钱之玉: "《药理学4版》", 31 August 2015, 中国医药科技出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113573711A (zh) * 2019-01-04 2021-10-29 伊瑟治疗公司 治疗药物或酒精依赖性的方法
CN114096249A (zh) * 2019-07-09 2022-02-25 奥瑞克索股份公司 用于鼻腔递送的药物组合物

Also Published As

Publication number Publication date
EP3400066B1 (en) 2021-07-28
EP3400066A4 (en) 2019-06-26
US20250177379A1 (en) 2025-06-05
WO2017120417A1 (en) 2017-07-13
JP7061568B2 (ja) 2022-04-28
EP3400066A1 (en) 2018-11-14
AU2017206041B2 (en) 2022-07-28
JP2019501194A (ja) 2019-01-17
US10925870B2 (en) 2021-02-23
US12161641B2 (en) 2024-12-10
DK3400066T3 (da) 2021-10-18
US20210205296A1 (en) 2021-07-08
AU2017206041A1 (en) 2018-07-26
CA3010609A1 (en) 2017-07-13
US20190015406A1 (en) 2019-01-17
NZ744112A (en) 2025-05-30

Similar Documents

Publication Publication Date Title
US12161641B2 (en) Treatments and prevention of opioid neonatal abstinence syndrome
KR102271048B1 (ko) 콜히친의 서방형 제형 및 이의 이용 방법
BRPI0707044B1 (pt) comprimido matricial insolúvel em água e processo de fabricação de comprimidos matriciais
KR20240023691A (ko) 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물
RU2696563C9 (ru) Композиционный препарат, включающий слой пленочного покрытия, содержащий активный ингредиент
TWI483738B (zh) 具有改良之味道遮蔽性的擠出物
JP2016172752A (ja) 排尿頻度を減少させるための延長放出製剤およびその使用の方法
JP2022501320A (ja) 抗血小板剤と胃酸分泌阻害剤を含む医薬組成物
WO2021171237A1 (en) Pharmaceutical composition for oral administration
JP2018039831A (ja) 排尿頻度を減少させるための医薬製剤およびその使用の方法
EP3302458B1 (en) Methods of preventing and treating autoimmunity
WO2009126606A2 (en) Regression of established atherosclerotic plaques, and treating sudden-onset asthma attacks, using parp inhibitors
KR20160011205A (ko) 히드로코티손을 포함하는 조성물
EP3949955A1 (en) Pharmaceutical composition comprising esomeprazole or pharmaceutically acceptable salt thereof and having double-release profile
HK1260764A1 (en) Treatments and prevention of opioid neonatal abstinence syndrome
CN115702935B (zh) 一种氯雷他定药物组合物及其制备方法
TWI775408B (zh) 用以治療與嗜中性白血球激活失調及趨化相關之疾病的方法
WO2017059726A1 (zh) 癸酸甘油三酯类化合物在制备治疗多囊卵巢综合症药物中的应用
JP2018529711A (ja) 排尿の頻度を低減するための組成物、ならびにその作製および使用方法
WO2018192469A1 (en) Inhibitors of fabp4 and methods of treating arthritis
US20240325379A1 (en) Low-dose naltrexol and uses thereof
JP2010013481A (ja) アムロジピン含有粒子およびそれからなる口腔内崩壊錠
HK40111880A (en) Low-dose naltrexol and uses thereof
RU2343908C1 (ru) Средство для профилактики и лечения алкоголизма и способ его применения
JP2018538279A (ja) 排尿の頻度を低減するための組成物、ならびにその作製および使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1260764

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20181109